{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:49:43Z","timestamp":1793832583392,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The clinical study NATIVE was funder by Inventiva."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial secondary and exploratory outcomes (ClinicalTrials.gov NCT03008070) were analyzed for the effect of lanifibranor on IR, lipid and glucose metabolism, systemic inflammation, blood pressure (BP), hepatic steatosis (imaging and histological grading) for all patients of the original analysis. With lanifibranor, triglycerides, HDL-C, apolipoproteins, insulin, HOMA-IR, HbA1c, fasting glucose (FG), hs-CRP, ferritin, diastolic BP and steatosis improved significantly, independent of diabetes status: most patients with prediabetes returned to normal FG levels. Significant adiponectin increases correlated with hepatic and CMH marker improvement; patients had an average weight gain of 2.5\u2009kg, with 49% gaining \u22652.5% weight. Therapeutic benefits were similar regardless of weight change. Here, we show that effects of lanifibranor on liver histology in MASH are accompanied with CMH improvement, indicative of potential cardiovascular clinical benefits.<\/jats:p>","DOI":"10.1038\/s41467-024-47919-9","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T11:01:58Z","timestamp":1715338918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3230-7591","authenticated-orcid":false,"given":"Michael P.","family":"Cooreman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Dzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot-Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Junien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Broqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven M.","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"47919_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos, A. F., Silva Junior, W. S. & Valerio, C. M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 12, 60 (2020).","journal-title":"Diabetol. Metab. Syndr."},{"key":"47919_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque, S. et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat. Rev. Gastroenterol. Hepatol. 18, 24\u201339 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47919_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"47919_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60\u201378 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47919_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","volume":"79","author":"AM Allen","year":"2023","unstructured":"Allen, A. M., Lazarus, J. V. & Younossi, Z. M. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J. Hepatol. 79, 209\u2013217 (2023).","journal-title":"J. Hepatol."},{"key":"47919_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","volume":"78","author":"JT Haas","year":"2016","unstructured":"Haas, J. T., Francque, S. & Staels, B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu. Rev. Physiol. 78, 181\u2013205 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"47919_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","volume":"21","author":"C Koliaki","year":"2015","unstructured":"Koliaki, C. et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21, 739\u2013746 (2015).","journal-title":"Cell Metab."},{"key":"47919_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe, R. F., Tabas, I. & Pajvani, U. B. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913\u20131928 (2020).","journal-title":"Gastroenterology"},{"key":"47919_CR9","doi-asserted-by":"crossref","unstructured":"Antar, S. A., Ashour, N. A., Marawan, M. E. & Al-Karmalawy, A. A. Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int. J. Mol. Sci. 24, 4004 (2023).","DOI":"10.3390\/ijms24044004"},{"key":"47919_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0035-1550065","volume":"35","author":"P Angulo","year":"2015","unstructured":"Angulo, P., Machado, M. V. & Diehl, A. M. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. Semin Liver Dis. 35, 132\u2013145 (2015).","journal-title":"Semin Liver Dis."},{"key":"47919_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"47919_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547\u20131554 (2015).","journal-title":"Hepatology"},{"key":"47919_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstrom","year":"2017","unstructured":"Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265\u20131273 (2017).","journal-title":"J. Hepatol."},{"key":"47919_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158, 1611\u20131625.e1612 (2020).","journal-title":"Gastroenterology"},{"key":"47919_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330\u2013344 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47919_CR16","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani, A. et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S, 154170 (2020).","journal-title":"Metabolism"},{"key":"47919_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65, 589\u2013600 (2016).","journal-title":"J. Hepatol."},{"key":"47919_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.amjcard.2022.02.012","volume":"171","author":"HM Salah","year":"2022","unstructured":"Salah, H. M. et al. Meta-analysis of nonalcoholic fatty liver disease and incident heart failure. Am. J. Cardiol. 171, 180\u2013181 (2022).","journal-title":"Am. J. Cardiol."},{"key":"47919_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12944-015-0038-x","volume":"14","author":"R Jin","year":"2015","unstructured":"Jin, R. et al. Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. Lipids Health Dis. 14, 39 (2015).","journal-title":"Lipids Health Dis."},{"key":"47919_CR20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper, P. et al. NAFLD and cardiovascular diseases: a clinical review. Clin. Res. Cardiol. 110, 921\u2013937 (2021).","journal-title":"Clin. Res. Cardiol."},{"key":"47919_CR21","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta, F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin. Gastroenterol. Hepatol. 18, 2324\u20132331.e2324 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"47919_CR22","doi-asserted-by":"publisher","first-page":"106766","DOI":"10.1016\/j.prostaglandins.2023.106766","volume":"169","author":"N Malladi","year":"2023","unstructured":"Malladi, N., Alam, M. J., Maulik, S. K. & Banerjee, S. K. The role of platelets in non-alcoholic fatty liver disease: from pathophysiology to therapeutics. Prostaglandins Other Lipid Mediat. 169, 106766 (2023).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"47919_CR23","doi-asserted-by":"publisher","first-page":"e0241357","DOI":"10.1371\/journal.pone.0241357","volume":"15","author":"JP Mann","year":"2020","unstructured":"Mann, J. P. et al. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS One 15, e0241357 (2020).","journal-title":"PLoS One"},{"key":"47919_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557\u20131565 (2017).","journal-title":"Hepatology"},{"key":"47919_CR25","doi-asserted-by":"publisher","first-page":"6696857","DOI":"10.1155\/2021\/6696857","volume":"2021","author":"S Chiriac","year":"2021","unstructured":"Chiriac, S. et al. Nonalcoholic fatty liver disease and cardiovascular diseases: the heart of the matter. Can. J. Gastroenterol. Hepatol. 2021, 6696857 (2021).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"47919_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100556","volume":"27","author":"P Golabi","year":"2022","unstructured":"Golabi, P. et al. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann. Hepatol. 27, 100556 (2022).","journal-title":"Ann. Hepatol."},{"key":"47919_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 69, 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"key":"47919_CR28","doi-asserted-by":"crossref","unstructured":"Staels, B., Butruille, L. & Francque, S. Treating NASH by targeting peroxisome proliferator-activated receptors. J. Hepatol. 79, 1302\u20131316 (2023).","DOI":"10.1016\/j.jhep.2023.07.004"},{"key":"47919_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/hep4.1057","volume":"1","author":"G Wettstein","year":"2017","unstructured":"Wettstein, G. et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol. Commun. 1, 524\u2013537 (2017).","journal-title":"Hepatol. Commun."},{"key":"47919_CR30","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","volume":"61","author":"B Boubia","year":"2018","unstructured":"Boubia, B. et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) alpha\/gamma\/delta triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate. J. Med. Chem. 61, 2246\u20132265 (2018).","journal-title":"J. Med. Chem."},{"key":"47919_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque, S. M. et al. A randomized, controlled trial of the Pan-PPAR Agonist Lanifibranor in NASH. N. Engl. J. Med. 385, 1547\u20131558 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47919_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston, N. A. et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation 140, 1308\u20131317 (2019).","journal-title":"Circulation"},{"key":"47919_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8732360","volume":"2022","author":"T Kandelouei","year":"2022","unstructured":"Kandelouei, T. et al. Effect of Statins on Serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm. 2022, 8732360 (2022).","journal-title":"Mediators Inflamm."},{"key":"47919_CR34","doi-asserted-by":"publisher","first-page":"619564","DOI":"10.3389\/fimmu.2020.619564","volume":"11","author":"RV Jimenez","year":"2020","unstructured":"Jimenez, R. V. & Szalai, A. J. Therapeutic lowering of C-Reactive Protein. Front. Immunol. 11, 619564 (2020).","journal-title":"Front. Immunol."},{"key":"47919_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson, T. A. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499\u2013511 (2003).","journal-title":"Circulation"},{"key":"47919_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20\u201328 (2005).","journal-title":"N. Engl. J. Med."},{"key":"47919_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12872-019-1068-5","volume":"19","author":"JR Liu","year":"2019","unstructured":"Liu, J. R., Liu, Y., Yin, F. Z. & Liu, B. W. Serum ferritin, an early marker of cardiovascular risk: a study in Chinese men of first-degree relatives with family history of type 2 diabetes. BMC Cardiovasc. Disord. 19, 82 (2019).","journal-title":"BMC Cardiovasc. Disord."},{"key":"47919_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1475-2840-9-15","volume":"9","author":"AZ Fu","year":"2010","unstructured":"Fu, A. Z., Qiu, Y., Radican, L., Yin, D. D. & Mavros, P. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. Cardiovasc. Diabetol. 9, 15 (2010).","journal-title":"Cardiovasc. Diabetol."},{"key":"47919_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/653789","volume":"2013","author":"AS Matheus","year":"2013","unstructured":"Matheus, A. S. et al. Impact of diabetes on cardiovascular disease: an update. Int. J. Hypertens. 2013, 653789 (2013).","journal-title":"Int. J. Hypertens."},{"key":"47919_CR40","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos, A. S. et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 74, 1220\u20131233 (2021).","journal-title":"Hepatology"},{"key":"47919_CR41","doi-asserted-by":"publisher","first-page":"e001776","DOI":"10.1136\/bmjdrc-2020-001776","volume":"9","author":"UP Gujral","year":"2021","unstructured":"Gujral, U. P. et al. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. BMJ Open Diabetes Res. Care 9, e001776 (2021).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"47919_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109980","volume":"190","author":"JS Neves","year":"2022","unstructured":"Neves, J. S. et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res. Clin. Pract. 190, 109980 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"47919_CR43","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes, P. J. et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717\u20131730 (2019).","journal-title":"Gastroenterology"},{"key":"47919_CR44","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1111\/liv.15005","volume":"41","author":"A Gastaldelli","year":"2021","unstructured":"Gastaldelli, A. et al. PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int. 41, 2659\u20132670 (2021).","journal-title":"Liver Int."},{"key":"47919_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","volume":"47","author":"B Balas","year":"2007","unstructured":"Balas, B. et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J. Hepatol. 47, 565\u2013570 (2007).","journal-title":"J. Hepatol."},{"key":"47919_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","volume":"1","author":"S Shadid","year":"2003","unstructured":"Shadid, S. & Jensen, M. D. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin. Gastroenterol. Hepatol. 1, 384\u2013387 (2003).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"47919_CR47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/diacare.29.03.06.dc05-2004","volume":"29","author":"A Basu","year":"2006","unstructured":"Basu, A. et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29, 510\u2013514 (2006).","journal-title":"Diabetes Care"},{"key":"47919_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00125-020-05281-7","volume":"64","author":"U White","year":"2021","unstructured":"White, U., Fitch, M. D., Beyl, R. A., Hellerstein, M. K. & Ravussin, E. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. Diabetologia 64, 159\u2013167 (2021).","journal-title":"Diabetologia"},{"key":"47919_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","volume":"1771","author":"A Rubenstrunk","year":"2007","unstructured":"Rubenstrunk, A., Hanf, R., Hum, D. W., Fruchart, J. C. & Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771, 1065\u20131081 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"47919_CR50","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.2337\/diabetes.54.12.3358","volume":"54","author":"A Tsuchida","year":"2005","unstructured":"Tsuchida, A. et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54, 3358\u20133370 (2005).","journal-title":"Diabetes"},{"key":"47919_CR51","doi-asserted-by":"publisher","first-page":"E164","DOI":"10.1152\/ajpendo.00219.2010","volume":"300","author":"G Hsiao","year":"2011","unstructured":"Hsiao, G. et al. Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats. Am. J. Physiol. Endocrinol. Metab. 300, E164\u2013E174 (2011).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"47919_CR52","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/FPC.0b013e328352a72e","volume":"22","author":"N Rasouli","year":"2012","unstructured":"Rasouli, N., Kern, P. A., Elbein, S. C., Sharma, N. K. & Das, S. K. Improved insulin sensitivity after treatment with PPARgamma and PPARalpha ligands is mediated by genetically modulated transcripts. Pharmacogenet. Genom. 22, 484\u2013497 (2012).","journal-title":"Pharmacogenet. Genom."},{"key":"47919_CR53","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli, A. & Cusi, K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 1, 312\u2013328 (2019).","journal-title":"JHEP Rep."},{"key":"47919_CR54","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/jc.2003-031315","volume":"89","author":"M Bajaj","year":"2004","unstructured":"Bajaj, M. et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89, 200\u2013206 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"47919_CR55","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297\u20132307 (2006).","journal-title":"N. Engl. J. Med."},{"key":"47919_CR56","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/hep.23116","volume":"50","author":"A Gastaldelli","year":"2009","unstructured":"Gastaldelli, A. et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087\u20131093 (2009).","journal-title":"Hepatology"},{"key":"47919_CR57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2036.2010.04405.x","volume":"32","author":"A Gastaldelli","year":"2010","unstructured":"Gastaldelli, A. et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharm. Ther. 32, 769\u2013775 (2010).","journal-title":"Aliment Pharm. Ther."},{"key":"47919_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","volume":"270","author":"TG Simon","year":"2018","unstructured":"Simon, T. G. et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int. J. Cardiol. 270, 245\u2013252 (2018).","journal-title":"Int. J. Cardiol."},{"key":"47919_CR59","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.5114\/aoms.2017.68821","volume":"14","author":"R Sao","year":"2018","unstructured":"Sao, R. & Aronow, W. S. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch. Med. Sci. 14, 1233\u20131244 (2018).","journal-title":"Arch. Med. Sci."},{"key":"47919_CR60","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.32519","volume":"76","author":"Y Shang","year":"2022","unstructured":"Shang, Y., Nasr, P., Widman, L. & Hagstrom, H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology 76, 1495\u20131505 (2022).","journal-title":"Hepatology"},{"key":"47919_CR61","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Toh, J. Z. K. et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 20, 2462\u20132473.e2410 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"47919_CR62","doi-asserted-by":"publisher","first-page":"e2578","DOI":"10.1097\/MD.0000000000002578","volume":"95","author":"DH Sinn","year":"2016","unstructured":"Sinn, D. H. et al. Nonalcoholic fatty liver disease for identification of preclinical carotid atherosclerosis. Medicine 95, e2578 (2016).","journal-title":"Medicine"},{"key":"47919_CR63","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69, 1691\u20131705 (2020).","journal-title":"Gut"},{"key":"47919_CR64","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee, Q. M., Mantovani, A., Tilg, H. & Targher, G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 15, 425\u2013439 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47919_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher, G., Corey, K. E., Byrne, C. D. & Roden, M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. 18, 599\u2013612 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47919_CR66","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan, N., Schick, F., Birkenfeld, A. L., Haring, H. U. & White, M. F. The role of hepatokines in NAFLD. Cell Metab. 35, 236\u2013252 (2023).","journal-title":"Cell Metab."},{"key":"47919_CR67","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa, P. & Consortium, F. P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60, 565\u2013575 (2014).","journal-title":"Hepatology"},{"key":"47919_CR68","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes, A.","year":"2018","unstructured":"American Diabetes, A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41, S13\u2013S27 (2018).","journal-title":"Diabetes Care"},{"key":"47919_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/dia.2006.8.28","volume":"8","author":"A Pfutzner","year":"2006","unstructured":"Pfutzner, A. & Forst, T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol. Ther. 8, 28\u201336 (2006).","journal-title":"Diabetes Technol. Ther."},{"key":"47919_CR70","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/CIRCRESAHA.120.314458","volume":"128","author":"S Zhao","year":"2021","unstructured":"Zhao, S., Kusminski, C. M. & Scherer, P. E. Adiponectin, Leptin and Cardiovascular Disorders. Circ. Res. 128, 136\u2013149 (2021).","journal-title":"Circ. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47919-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47919-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47919-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T11:05:07Z","timestamp":1715339107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47919-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["47919"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-47919-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P.C., L.D., P.H.M., M.B. and P.B. are employees of Inventiva. J.L.J. is a consultant for Inventiva. D.R.B. has received honoraria from Inventiva via Translational Medicine Academy. J.B. has served as a consultant for Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, Cardiorem, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll. RPG received research support or honoraria form Amgen, Anthos Therapeutics, Daiichi Sankyo, Ionis, Dr. Reddy\u2019s Laboratories, Medical Education Resources, Menarini, SAJA Pharmaceuticals, Servier, SUMMEET, and consults for Artivion, Beckman Coulter, Daiichi Sankyo, Gilead, Inari, Inventiva, PhaseBio Pharmaceuticals, Samsung and Aventis. FZ reports personal fees from 89Bio, Abbott, Acceleron, Applied Therapeutics, Bayer, Betagenon, Boehringer, BMS, CVRx, Cambrian, Cardior, Cereno pharmaceutical, Cellprothera, CEVA, Inventiva, KBP, Merck, NovoNordisk, Owkin, Otsuka, Roche Diagnostics, Northsea, USa2, having stock options at G3Pharmaceutical and equities at Cereno, Cardiorenal, Eshmoun Clinical research and being the founder of Cardiovascular Clinical Trialists. MFA received grants from Boehringer-Ingelheim, Gilead, Hanmi, Inventiva, Madrigal, Novo Nordisk; honoraria from Clinical Care Options, Fishawack, Medscape, Terra Firma, CLDF; royalties from Up-to-Date; consults for 89Bio, BMS, Hanmi, Inventiva, Intercept, Madrigal, Merck, Novo Nordisk. SMF received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche; honoraria from Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens; serves as consultant for Abbvie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Alnylam, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Dr. Falk Pharma, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Biosciences, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, PRO.MED.CS Praha, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, Mursla Bio, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, Siemens Healthineers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3962"}}